Loading...
XJPX
2160
Market cap833mUSD
Dec 05, Last price  
2,329.00JPY
1D
0.87%
1Q
-12.80%
Jan 2017
220.50%
IPO
762.59%
Name

GNI Group Ltd

Chart & Performance

D1W1MN
XJPX:2160 chart
P/E
132.44
P/S
5.48
EPS
17.59
Div Yield, %
—
Shrs. gr., 5y
3.56%
Rev. gr., 5y
25.96%
Revenues
23.61b
-9.22%
273,588,000204,346,000272,876,00090,332,000161,943,000183,600,000474,717,0001,016,670,0001,306,931,0002,648,451,0005,018,944,0007,446,067,0009,773,862,00012,690,246,00017,418,966,00026,010,571,00023,611,705,000
Net income
978m
-87.92%
-1,279,454,000-1,366,385,000-258,088,000-435,450,000-482,255,000-730,776,000-327,953,000-623,150,000-513,101,000-175,206,000192,173,000629,919,0001,258,127,00055,243,000-868,252,0008,094,202,000977,658,000
CFO
-3.16b
L
-1,031,582,000-942,814,000-130,543,000-163,989,000-351,819,000-662,821,000-567,075,000-382,203,000-518,714,000-315,226,000610,230,000788,587,0001,377,519,000552,268,000393,320,0006,549,337,000-3,164,422,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.
URL
https://www.gnipharma.com/
IPO date
Aug 31, 2007
Employees
701
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT